Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C

NCT01344798 is registered in ClinicalTrials.gov with Genethon as lead sponsor.

NCT NCT01344798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01344798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C
Lead sponsor
Genethon
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2006
Completion date
June 30, 2010
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gamma-sarcoglycanopathy, limb girdle muscular dystrophy type 2c